Rabeprazole

ATC Code A02BC04

Rabeprazole

Definition

An alpha-pyridylmethylsulfinyl benzimidazole and a selective and irreversible proton pump inhibitor with antisecretory property. Rabeprazole enters the parietal cell and accumulates in the acidic secretory canaliculi where the agent is activated by a proton-catalyzed process that results in the formation of a thiophilic sulfonamide or sulfenic acid. The activated rabeprazole forms covalent bonds with the sulfhydryl amino acids cysteine on the extracellular domain of the proton pump (H+/K+ ATPase) at the secretory surface, thereby inhibiting the transport of hydrogen ions, via exchange with potassium ions, into the gastric lumen. Binding to cysteine 813, in particular, is essential for inhibition of gastric acid production.

Also known as 2-(((4-(3-Methoxypropoxy)-3-methyl-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole, LY307640, RABEPRAZOLE — per NCIT

Also identified as

Indications

Disease Relation Source
Duodenal ulcer may treat MEDRT · Public domain (U.S. Government work)
Gastroesophageal reflux disease may treat MEDRT · Public domain (U.S. Government work)
Helicobacter pylori infectious disease may treat MEDRT · Public domain (U.S. Government work)
Zollinger-Ellison syndrome may treat MEDRT · Public domain (U.S. Government work)

Organ Effects

Organ Side effect / interaction Source
Alimentary part of gastrointestinal system may treat a disease of this organ DERIVED · CC BY 4.0
Esophagus may treat a disease of this organ DERIVED · CC BY 4.0
Intestine may treat a disease of this organ DERIVED · CC BY 4.0
Small intestine may treat a disease of this organ DERIVED · CC BY 4.0
Upper digestive tract may treat a disease of this organ DERIVED · CC BY 4.0

5 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.